The changes broaden eligibility for patients and permit more therapeutic options once enrolled in this randomized phase 3 trial, which explores the addition of radiotherapy to the usual treatment (chemotherapy) in people with esophagus and stomach cancer with limited spread
EA2212 is a randomized phase 2 study assessing if chemotherapy plus immunotherapy is superior to immunotherapy alone for patients with operable MSI-H/dMMR gastric and/or gastroesophageal junction cancer
This randomized phase 2 study is assessing if chemotherapy plus immunotherapy is superior to immunotherapy alone for patients with operable MSI-H/dMMR gastric and/or gastroesophageal junction cancer